Ocugen, Inc.

51 articles with Ocugen, Inc.

• Ocugen to Present at the GCFF Virtual Conference - Diversified Investing Strategies

  10/29/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the Global Chinese Financial Forum (GCFF) Virtual Conference—Diversified Investing Strategies  on November 5 at 1:45 p.m. Eastern Time. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the devel

• CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference

  10/22/2020

  Ocugen, Inc. announced Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on the importance of strategic partnerships in gene therapy including product consistency, identifying the right partner as well as providing examples of successful partnerships at the 4th Annual Gene Therapy for Rare Disorders Europe Conference from October 26-28, 2020 presented digitally.

• Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

  10/16/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET. Ocugen management, including Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Sanjay Subramanian, CFO, Dr. Mohamed Genead, Acting CMO and Ch

• Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned

  10/6/2020

  Ocugen, Inc. , (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it has entered into an agreement with Kemwell Biopharma Pvt. Ltd. (Kemwell) to manufacture OCU200 , Ocugen’s novel biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic

• Ocugen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/16/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21 at 1:40 p.m. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough modifi

• Ocugen Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

  9/8/2020

  Ocugen, Inc. announced that the Company received a letter from the Listing Qualification Department of The NASDAQ Capital Market notifying that Ocugen has been granted an additional 180-day compliance period or until March 8, 2021, to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550.

• Ocugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/3/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15 at 3 p.m. ET. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough

• Ocugen to Present at the LD 500 Virtual Investor Conference

  8/28/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the LD 500 Virtual Investor Conference on Friday, September 4 at 11 a.m. ET. Sanjay Subramanian, Chief Financial Officer, will present virtually to an online audience highlighting Ocugen’s breakthrough gene therapy platform as well as its

• Ocugen Provides Business Update and Second Quarter 2020 Financial Results

  8/14/2020

  Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8:30 a.m. ET

• Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

  8/10/2020

  Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases

• Ocugen to Host Conference Call on Friday, August 14 at 8:30 a.m. ET to Discuss Second Quarter 2020 Financial Results and Provide Business Update

  8/6/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that it will host a conference call to discuss its Q2 2020 financial results

• Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

  7/27/2020

  Third orphan drug designation for the same product, OCU400, is unique in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Degenerative diseases (IRDs)

• Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

  7/21/2020

  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug Congress USA 2020 Conference, to be held virtually from August 24-27, 2020.

• Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

  6/3/2020

  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved eye diseases, today announced the appointment of Dr. Mohamed Genead as chair of the Ocugen, Inc. Retina Scientific Advisory Board, which is comprised of prominent experts who provide strategic advice, clinical and regulatory support, and scientific and industry expertise. Shankar Musu

• Ocugen to Discontinue Phase 3 oGVHD TrialBreakthrough Modifier Gene Therapy platform continues to advance towards clinic

  6/1/2020

  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the Phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent Data Monitoring Committee, which indicated the trial

• Ocugen Provides Business Update and First Quarter 2020 Financial Results100% of planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020

  5/8/2020

  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today reported first quarter 2020 financial results along with a general business update. “We reached a significant milestone in our Phase 3 trial with OCU300 for ocular Graft vs. Host Disease (oGVHD) with the completion of our planned enrollment. We expect topline results by the end of this

• Ocugen Announces Completion of Warrant ExchangeAmendment and Exchange of Series A warrants removes the overhang in capital structure

  4/22/2020

  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the amendment and exchange (the “Exchange”) of the Series A warrants issued pursuant to the Securities Purchase Agreement dated June 13, 2019 (“SPA”) with the holders of all outstanding Series A warrants.

• Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors

  4/7/2020

  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the appointment of Kirsten Castillo and Prabhavathi Fernandes, Ph.D. to its board of directors.

• Ocugen Provides Business Update and Full Year 2019 Financial Results

  3/27/2020

  Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., March 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today reported full year 2019 financial results along with a general business update. “We are extremel

• Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update

  3/20/2020

  Ocugen, Inc. today announced that it will release its 2019 financial results and provide a business update before the open of the U.S. financial markets on Friday, March 27, 2020.  The company will host a conference call at 8:30 a.m. ET on the same day to discuss the resul